Home/Pipeline/Motpoly XR™

Motpoly XR™

Epilepsy

Not Specified (Likely Phase 3/NDA)Active

Key Facts

Indication

Epilepsy

Phase

Not Specified (Likely Phase 3/NDA)

Status

Active

Company

Aucta Pharmaceuticals

About Aucta Pharmaceuticals

Aucta Pharmaceuticals is a private, US-based specialty pharma company with a dual-site R&D and manufacturing presence in New Jersey and Shanghai. Its strategy centers on using its proprietary AucPed, AucTrol, and AucMist technology platforms to create differentiated dosage forms of established drugs, aiming to improve patient adherence and outcomes. The company is backed by a consortium of global and China-based healthcare investors and is advancing a pipeline focused on CNS and orphan diseases.

View full company profile

Therapeutic Areas

Central Nervous System (CNS) Disorders Metabolic Diseases Orphan and Specialty Indications Ophthalmics Dermatology Pediatrics

Other Epilepsy Drugs

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active
GABA-A PAM for Epilepsy	Modulate Bio	Preclinical	Active